Faculty profile

Arndt Vogel

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Arndt Vogel

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
96 publications in the last five years, latest in 2026.
Senior (last) author on 18 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Cholangiocarcinoma Targeted Therapies

Latest papers

The rise of transplant oncology in primary liver cancer and metastatic disease.
Hepatology (Baltimore, Md.) · 2026
Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies.
Gut · 2026
Precision oncology in GI-cancers: Mechanisms of action, indications and ongoing strategies to overcome primary and secondary resistance.
Seminars in cancer biology · 2026 · senior author

All 96 publications

Latest funding

A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study)
CIHR · 2025 · Co-investigator
$210,000
Patient-derived models for the Research and Evaluation of Discovery and Innovation in Combination Therapies for Biliary tract Cancer
CIHR · 2024 · Nominated PI
$279,166

All 2 grants and awards

96 publications.

The rise of transplant oncology in primary liver cancer and metastatic disease.

Wassmer CH, Gelli M, Wong TCL, Li Z, Zorigtbaatar A, Marino R, Aceituno Sierra L, Adam R, Chan ACY, Heimbach J, Line PD, Mazzaferro V, Sapisochin G, Tabrizian P, Vogel A, Toso C

Hepatology (Baltimore, Md.)2026

DOI: 10.1097/hep.0000000000001723 PMID: 41746604

Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies.

Yarchoan M, Llovet JM, Kelley RK, Finn R, Parikh ND, Tabrizian P, Burgoyne AM, Agopian VG, Sanford NN, Tran Cao HS, Padia SA, Vogel A, Lewandowski RJ, Kirema GR, Lin R, Mehta N, Sapisochin G, Yopp A, Villanueva A, Halazun K, Pinato DJ, Kim E, Heimbach JK, Pillai A, Salem R, El-Khoueiry A, Singal AG

Gut2026

DOI: 10.1136/gutjnl-2026-339505 PMID: 42785981

Precision oncology in GI-cancers: Mechanisms of action, indications and ongoing strategies to overcome primary and secondary resistance.

Aceituno L, Valenzi E, Segatto O, Saborowski A, Vogel A

Seminars in cancer biology2026Senior author

DOI: 10.1016/j.semcancer.2026.102619 PMID: 42764109

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study.

Persano M, Casadei-Gardini A, Fornaro L, Satake T, Abidoye O, Lo Prinzi F, Antonuzzo L, Kim JW, Bergamo F, Bathon M, Saborowski A, Pressiani T, Vivaldi C, Rapposelli IG, Peeters F, Braconi C, Pinato DJ, Tamburini E, Niger M, Tamberi S, Castet F, Verrico M, Parisi A, Couto N, Chon HJ, Lamarca A, Giordano G, Finkelmeier F, Oneda E, Avallone A, Perkhofer L, Kim IH, Garajova I, Corallo S, Fenocchio E, Dell'Aquila E, Pirrone C, Lucidi L, Tesini G, Valenzi E, Diana A, Yoo C, Schirripa M, Formica V, Rodriquenz MG, Scartozzi M, Adeva J, Ghidini M, Prager GW, Aprile G, Spinelli GP, Yung-Yeh S, Chan SL, Ikeda M, Bekaii-Saab T, Lucchetti J, Lavacchi D, Kang M, Balsano R, Salani F, Camera S, Masi G, Lonardi S, Vogel A, Rimassa L, Rimini M

Cancer2026

DOI: 10.1002/cncr.70601 PMID: 42745498

Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns.

Casalino S, Scarlato E, Cruz MC, Gerdes C, Sordo A, Quinzii A, Zecchetto C, Messineo L, Tasselli E, Mendo L, Saborowski A, Bridgewater J, Vogel A, Melisi D

European journal of cancer (Oxford, England : 1990)2026

DOI: 10.1016/j.ejca.2026.117036 PMID: 42731348

Expanding the path to cure - a narrative review on optimizing multimodality sequencing in HCC.

Lim HJ, Vogel A, Dunne EM, Brahmania M, Tam VC, Abraham RJ, Knox JJ, Wong JK, Chaudhury P, Ramjeesingh R, Kim PTW, Martins I, Leite LC, Valenti D, Sapisochin G, Liu DM

Cancer treatment reviews2026

DOI: 10.1016/j.ctrv.2026.103194 PMID: 42492407

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial.

Oh DY, He AR, Qin S, Chen LT, Okusaka T, Griffin R, Wang J, Xynos I, Vogel A, Valle JW

JAMA oncology2026

DOI: 10.1001/jamaoncol.2026.2204 PMID: 42424063

Beyond rejection risk: Identifying ideal candidates for pretransplant immune checkpoint inhibitors for HCC.

Aceituno L, O'Kane GM, Choi WJ, Tarbizian P, Bucur R, Rukavina N, Zorigtbaatar A, Mínguez B, Vogel A, Sapisochin G

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2026

DOI: 10.1097/lvt.0000000000000829 PMID: 41855385

Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.

Prinzi FL, Rimini M, Ikeda M, Abidoye O, Lucchetti J, Antonuzzo L, Kim JW, Nichetti F, Saborowski A, Pressiani T, Vivaldi C, Rapposelli IG, Peeters F, Braconi C, Pinato DJ, Tamburini E, Pircher C, Tamberi S, Castet F, Verrico M, Parisi A, Couto N, Chon HJ, Martirena A, Lamarca A, Landriscina M, Finkelmeier F, Oneda E, Avallone A, Dell'Aquila E, Perkhofer L, Kim IH, Formica V, de Sousa Pinto CM, Garajova I, Kang B, Corallo S, Fenocchio E, Farinea G, Pastorino A, Diana A, Changhoon Y, Schirripa M, Rodriquenz MG, Scartozzi M, Zumstein L, Ghidini M, Prager GW, Aprile G, Spinelli GP, Yung-Yeh S, Chan SL, Warmington E, Lancianese A, Satake T, Bekaii-Saab T, Giordano G, Lavacchi D, Passeri L, Ferrara M, Kang M, Prete AA, Bozzarelli S, Persano M, Masi G, Balsano R, Niger M, Lonardi S, Salani F, Camera S, Vogel A, Fornaro L, Rimassa L, Casadei-Gardini A

International journal of cancer2026

DOI: 10.1002/ijc.70699 PMID: 42581755

Sequencing of Fibroblast Growth Factor Receptor Inhibitors in Cholangiocarcinoma: A Review of Published Cases.

Dilg D, Blecker M, Vivancos A, Macarulla T, Vogel A

JCO precision oncology2026Senior author

DOI: 10.1200/po-25-01099 PMID: 42679332

Something wrong or missing on this profile? Suggest a correction

Arndt Vogel

Research

Latest papers

Latest funding

The rise of transplant oncology in primary liver cancer and metastatic disease.

Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies.

Precision oncology in GI-cancers: Mechanisms of action, indications and ongoing strategies to overcome primary and secondary resistance.

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study.

Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns.

Expanding the path to cure - a narrative review on optimizing multimodality sequencing in HCC.

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial.

Beyond rejection risk: Identifying ideal candidates for pretransplant immune checkpoint inhibitors for HCC.

Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.

Sequencing of Fibroblast Growth Factor Receptor Inhibitors in Cholangiocarcinoma: A Review of Published Cases.

A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study)

Patient-derived models for the Research and Evaluation of Discovery and Innovation in Combination Therapies for Biliary tract Cancer

Frequent collaborators

Gonzalo Sapisochin

Michael Yan

Steven Gallinger

Robert Grant

Faiyaz Notta

Ian Mcgilvray

Nazia Selzner

Mamatha Bhat

Anand Ghanekar

Rob Beecroft

Benjamin Haibe-Kains

Daniel De Carvalho

Markus Selzner

Brandon Meyers

Girish Kulkarni

John Kim

James Chow

Gregory Schwartz

Mark Cattral

Gang Zheng

Samuel Saibil

Jelena Lukovic